In early 2024, a new therapeutic option, Resmetirom, a liver-directed thyroid hormone receptor beta (THR-β) agonist, became available in the United States for individuals with MASH having moderate to advanced liver fibrosis (F2-F3), offering a targeted approach to treatment. This evidence concerns the gene THRB and metabolic dysfunction-associated steatohepatitis.